Search - tctmd.com

Displaying 121 - 138 of 138

Sort: Relevancy | Date

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

Presentation

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Presenter: Vivek Y. Reddy

January 29, 2013

News Daily News

Renal Denervation Shows Sustained BP Improvements at 1 Year

Jason Kahn

December 26, 2012

Presentation TCT 2012

Contrast Nephropathy: Risk Scores and Prophylaxis

Presenter: Carlo Briguori

October 22, 2012

News Daily News

Meta-analysis Takes an Indirect Look at Differences Among Novel Anticoagulants

September 11, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

Induced Diuresis with Matched Hydration Reduces Contrast Nephropathy

January 17, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

News Daily News

Pre-PCI Hydration Feasible, Reduces Kidney Damage in STEMI Patients

Caitlin E. Cox

October 07, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

News Daily News

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

L.A. McKeown

August 16, 2011

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Daily News

Letters to Lancet Take on PCI Substudy of CURRENT-OASIS 7

Caitlin E. Cox

January 25, 2011

Advertisement

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Renal Denervation Shows Sustained BP Improvements at 1 Year

Contrast Nephropathy: Risk Scores and Prophylaxis

Meta-analysis Takes an Indirect Look at Differences Among Novel Anticoagulants

Watchman Works Just as Well Without Warfarin-Protected Transition

Induced Diuresis with Matched Hydration Reduces Contrast Nephropathy

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

Pre-PCI Hydration Feasible, Reduces Kidney Damage in STEMI Patients

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

Carbon Dioxide Angiography May Be Alternative to Iodinated Contrast in High-Risk Patients

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Letters to Lancet Take on PCI Substudy of CURRENT-OASIS 7

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content